B-intervention	0	6	Stress
I-intervention	7	17	management
O	18	25	reduces
B-condition	26	41	intraindividual
I-condition	42	50	cortisol
I-condition	51	62	variability
O	62	63	,
O	64	69	while
O	70	73	not
O	74	83	impacting
O	84	89	other
O	90	98	measures
O	99	101	of
O	102	110	cortisol
O	111	117	rhythm
O	117	118	,
O	119	121	in
O	122	123	a
O	124	129	group
O	130	132	of
O	133	138	women
O	139	141	at
O	142	146	risk
O	147	150	for
O	151	157	breast
O	158	164	cancer
O	164	165	.

O	166	169	The
O	170	176	stress
O	177	184	hormone
O	185	193	cortisol
O	194	202	exhibits
O	203	204	a
O	205	212	diurnal
O	213	219	rhythm
O	220	230	throughout
O	231	234	the
O	235	238	day
O	238	239	,
O	240	242	as
O	243	247	well
O	248	250	as
O	251	257	within
O	258	264	person
O	265	276	variability
O	276	277	.

O	278	284	Recent
O	285	296	statistical
O	297	307	approaches
O	308	313	allow
O	314	317	for
O	318	321	the
O	322	332	estimation
O	333	335	of
O	336	351	intraindividual
O	352	360	cortisol
O	361	372	variability
O	373	374	(
O	374	375	"
O	375	378	ICV
O	378	379	"
O	379	380	)
O	381	384	and
O	385	386	a
O	387	394	greater
O	395	398	ICV
O	399	402	has
O	403	407	been
O	408	416	observed
O	417	419	in
O	420	424	some
O	425	429	mood
O	430	439	disorders
O	440	441	(
O	441	446	major
O	447	457	depression
O	457	458	,
O	459	467	remitted
O	468	475	bipolar
O	476	484	disorder
O	484	485	)
O	485	486	;
O	487	494	however
O	494	495	,
O	496	499	ICV
O	500	503	has
O	504	507	not
O	508	512	been
O	513	521	examined
O	522	531	following
O	532	538	stress
O	539	549	management
O	549	550	.

O	551	553	In
O	554	558	this
O	559	568	secondary
O	569	577	analyses
O	578	580	of
O	581	583	an
O	584	595	efficacious
O	596	606	randomized
O	607	615	clinical
O	616	621	trial
O	621	622	,
O	623	625	we
O	626	633	examine
O	634	637	how
O	638	641	ICV
O	642	645	may
O	646	652	change
O	653	658	after
O	659	668	cognitive
O	669	679	behavioral
O	680	686	stress
O	687	697	management
O	698	699	(
O	699	703	CBSM
O	703	704	)
B-eligibility	705	710	among
I-eligibility	711	718	healthy
I-eligibility	719	727	stressed
I-eligibility	728	733	women
I-eligibility	734	736	at
I-eligibility	737	741	risk
I-eligibility	742	745	for
I-eligibility	746	752	breast
I-eligibility	753	759	cancer
O	759	760	.

O	761	767	Second
O	767	768	,
O	769	771	we
O	772	784	concurrently
O	785	792	compare
O	793	798	other
O	799	811	calculations
O	812	814	of
O	815	823	cortisol
O	824	828	that
O	829	832	may
O	833	839	change
O	840	849	following
O	850	854	CBSM
O	854	855	.

O	856	866	Multilevel
O	867	875	modeling
O	876	877	(
O	877	880	MLM
O	880	881	)
O	882	885	was
O	886	893	applied
O	894	896	to
O	897	905	estimate
O	906	909	ICV
O	910	913	and
O	914	916	to
O	917	921	test
O	922	925	for
O	926	927	a
O	928	933	group
O	934	936	by
O	937	941	time
O	942	953	interaction
O	954	958	from
O	959	967	baseline
O	967	968	,
O	969	973	post
O	973	974	-
O	974	986	intervention
O	986	987	,
O	988	990	to
O	991	992	1
O	993	998	month
O	999	1008	following
O	1009	1013	CBSM
O	1013	1014	.

B-intervention-participants	1015	1020	Forty
I-intervention-participants	1020	1021	-
I-intervention-participants	1021	1025	four
O	1026	1031	women
O	1032	1036	were
O	1037	1047	randomized
O	1048	1050	to
O	1051	1054	the
O	1055	1059	CBSM
O	1059	1060	;
B-control-participants	1061	1063	47
O	1064	1066	to
O	1067	1070	the
B-control	1071	1081	comparison
I-control	1082	1087	group
O	1087	1088	;
O	1089	1093	mean
O	1094	1097	age
O	1098	1100	of
O	1101	1104	the
O	1105	1111	entire
O	1112	1117	group
O	1118	1121	was
O	1122	1124	44
O	1124	1125	.
O	1125	1126	2
O	1127	1128	(
O	1128	1130	SD
O	1130	1131	=
O	1131	1133	10
O	1133	1134	.
O	1134	1136	27
O	1136	1137	)
O	1137	1138	.

O	1139	1144	After
O	1145	1156	controlling
O	1157	1160	for
O	1161	1169	relevant
O	1170	1180	covariates
O	1180	1181	,
O	1182	1183	a
O	1184	1195	significant
O	1196	1200	time
O	1201	1203	by
O	1204	1209	group
O	1210	1221	interaction
O	1222	1229	emerged
O	1230	1231	(
O	1231	1232	β
O	1233	1241	estimate
O	1241	1242	=
O	1242	1243	-
O	1243	1244	.
O	1244	1247	070
O	1247	1248	;
O	1249	1250	p
O	1250	1251	<
O	1251	1252	.
O	1252	1254	05
O	1254	1255	)
O	1255	1256	,
O	1257	1261	such
O	1262	1266	that
O	1267	1271	CBSM
O	1272	1284	participants
O	1285	1297	demonstrated
O	1298	1299	a
O	1300	1305	lower
B-outcome	1306	1309	ICV
O	1310	1319	following
O	1320	1324	CBSM
O	1325	1333	compared
O	1334	1336	to
O	1337	1340	the
O	1341	1351	comparison
O	1352	1357	group
O	1357	1358	.

O	1359	1362	The
O	1363	1374	interaction
O	1375	1378	for
O	1379	1387	cortisol
O	1388	1393	slope
O	1394	1397	and
O	1398	1406	cortisol
O	1407	1413	output
O	1414	1415	(
O	1415	1419	area
O	1420	1425	under
O	1426	1429	the
O	1430	1435	curve
O	1435	1436	)
O	1437	1447	approached
O	1448	1460	significance
O	1461	1462	(
O	1462	1463	β
O	1464	1473	estimates
O	1473	1474	=
O	1474	1475	-
O	1475	1476	.
O	1476	1478	10
O	1479	1482	and
O	1483	1484	-
O	1484	1485	.
O	1485	1488	062
O	1488	1489	,
O	1490	1502	respectively
O	1502	1503	;
O	1504	1505	p
O	1505	1506	'
O	1506	1507	s
O	1507	1508	<
O	1508	1509	.
O	1509	1511	08
O	1511	1512	)
O	1512	1513	,
O	1514	1519	while
O	1520	1525	other
O	1526	1534	cortisol
O	1535	1543	outcomes
O	1544	1550	tested
O	1551	1555	were
O	1556	1559	not
O	1560	1573	significantly
O	1574	1581	changed
O	1582	1591	following
O	1592	1596	CBSM
O	1596	1597	.

O	1598	1601	ICV
O	1602	1605	may
O	1606	1615	represent
O	1616	1617	a
O	1618	1623	novel
O	1624	1629	index
O	1630	1632	of
O	1633	1641	cortisol
O	1642	1655	dysregulation
O	1656	1660	that
O	1661	1663	is
O	1664	1672	impacted
O	1673	1675	by
O	1676	1680	CBSM
O	1681	1684	and
O	1685	1688	may
O	1689	1698	represent
O	1699	1700	a
O	1701	1705	more
O	1706	1715	malleable
O	1716	1722	within
O	1722	1723	-
O	1723	1729	person
O	1730	1741	calculation
O	1742	1746	than
O	1747	1752	other
O	1752	1753	,
O	1754	1760	widely
O	1761	1768	applied
O	1769	1777	cortisol
O	1778	1786	outcomes
O	1786	1787	.

O	1788	1794	Future
O	1795	1803	research
O	1804	1810	should
O	1811	1818	examine
O	1819	1824	these
O	1825	1838	relationships
O	1839	1841	in
O	1842	1848	larger
O	1849	1856	samples
O	1856	1857	,
O	1858	1861	and
O	1862	1869	examine
O	1870	1873	ICV
O	1874	1877	and
O	1878	1884	health
O	1885	1893	outcomes
O	1893	1894	.

O	1895	1906	NCT01048528
O	1906	1907	.
